BioCentury | Sep 13, 2018
Emerging Company Profile

Mapping tumor markers

...discovery, and that is space or locality.” The company’s Spatial Processing And Regional Tumor Analysis (SPARTA...
...section has 300 to 500 images, which each have about nine million data points. The SPARTA...
...among patients who are unresponsive or resistant to immunotherapy. Starting in 2016, BioGraph 55 applied SPARTA...
BioCentury | May 9, 2016
Clinical News

PRTX-100: Preliminary Phase I/II data

...the per protocol (PP) population of part 1 of the 2-part, open-label, U.S. Phase I/II SPARTA-II...
...and then once monthly for 5 months in 11 patients who completed the Phase Ib SPARTA...
...with active RA (see BioCentury, Feb. 17, 2014 & Nov. 24, 2014). Part 2 of SPARTA-II...
BioCentury | Feb 16, 2015
Clinical News

ACH-3102: Additional Phase II data

...17, 2014 & Jan. 5, 2015). This half, Achillion plans to start the Phase II SPARTA...
BioCentury | Feb 10, 2015
Top Story

Achillion climbs on ACH-3102 data

...NS5B polymerase. Achillion spokesperson Glenn Schulman said the company plans to start the Phase II SPARTA...
BioCentury | Nov 24, 2014
Clinical News

PRTX-100: Additional Phase Ib data

...with active RA in the first 5 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA...
BioCentury | Jul 28, 2014
Financial News

Augmenix completes venture financing

...2014-07-23 Type: Venture financing Raised: $10.8 million Investors: CHV II; Excelestar Ventures; Catalyst Health Ventures; Sparta...
BioCentury | Feb 17, 2014
Clinical News

PRTX-100: Interim Phase Ib data

...with active RA in the first 4 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA...
BioCentury | Apr 15, 2013
Company News

Sparta other research news

...as tPA, as well as for other acute inflammatory reactions such as ARDS and trauma. Sparta Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

Sparta regulatory update

...are in preclinical development in acute pulmonary inflammation and reperfusion injury such as thrombo-embolic stroke. Sparta Pharmaceuticals Inc....
BioCentury | Feb 4, 2013
Financial News

Ocular Therapeutix financial update

...the company's existing institutional investors participated, including Polaris Venture Partners; Versant Ventures; SV Life Sciences; Sparta...
Items per page:
1 - 10 of 46
BioCentury | Sep 13, 2018
Emerging Company Profile

Mapping tumor markers

...discovery, and that is space or locality.” The company’s Spatial Processing And Regional Tumor Analysis (SPARTA...
...section has 300 to 500 images, which each have about nine million data points. The SPARTA...
...among patients who are unresponsive or resistant to immunotherapy. Starting in 2016, BioGraph 55 applied SPARTA...
BioCentury | May 9, 2016
Clinical News

PRTX-100: Preliminary Phase I/II data

...the per protocol (PP) population of part 1 of the 2-part, open-label, U.S. Phase I/II SPARTA-II...
...and then once monthly for 5 months in 11 patients who completed the Phase Ib SPARTA...
...with active RA (see BioCentury, Feb. 17, 2014 & Nov. 24, 2014). Part 2 of SPARTA-II...
BioCentury | Feb 16, 2015
Clinical News

ACH-3102: Additional Phase II data

...17, 2014 & Jan. 5, 2015). This half, Achillion plans to start the Phase II SPARTA...
BioCentury | Feb 10, 2015
Top Story

Achillion climbs on ACH-3102 data

...NS5B polymerase. Achillion spokesperson Glenn Schulman said the company plans to start the Phase II SPARTA...
BioCentury | Nov 24, 2014
Clinical News

PRTX-100: Additional Phase Ib data

...with active RA in the first 5 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA...
BioCentury | Jul 28, 2014
Financial News

Augmenix completes venture financing

...2014-07-23 Type: Venture financing Raised: $10.8 million Investors: CHV II; Excelestar Ventures; Catalyst Health Ventures; Sparta...
BioCentury | Feb 17, 2014
Clinical News

PRTX-100: Interim Phase Ib data

...with active RA in the first 4 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA...
BioCentury | Apr 15, 2013
Company News

Sparta other research news

...as tPA, as well as for other acute inflammatory reactions such as ARDS and trauma. Sparta Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

Sparta regulatory update

...are in preclinical development in acute pulmonary inflammation and reperfusion injury such as thrombo-embolic stroke. Sparta Pharmaceuticals Inc....
BioCentury | Feb 4, 2013
Financial News

Ocular Therapeutix financial update

...the company's existing institutional investors participated, including Polaris Venture Partners; Versant Ventures; SV Life Sciences; Sparta...
Items per page:
1 - 10 of 46